Nanopharmaceuticals are drugs or a therapeutic delivery system that operates at the nanoscale level. The novel approach can be used for early detection and treatment of various chronic diseases such as cancer. Therefore, increasing the prevalence of cancer and the adoption of targeted therapies for the treatment of the disease is expected to propel the growth of the EMEA nanopharmaceuticals market. For instance, according to a study published in the European Journal of Cancer in August 2018, cancer is now the leading cause of premature death (defined as death below the age of 70 years) in 28 of the 40 European countries and is the second most common in the remaining countries.
Nanopharmaceuticals offer site-specific targeting of active agents. This has led several governments to invest in R&D related to targeted therapies, which is also expected to boost growth of the market. For instance, according to the International Cancer Research Partnership for the United Kingdom (UK), France and the Netherlands (for 2014 and 2015), 57% of funding from government and nongovernment organization sectors was assigned to therapy‐oriented biology and drug development with 7% to prevention and 13% each to aetiology and to early detection, diagnosis and prognosis. Moreover, in December 2019, Ministry of Science, Research and Technology of Iran unveiled plans for the establishment of four new innovation factories across the country. The Azadi Innovation Factory started in western Tehran under this initiative, includes 10 separate sections and a central building providing opportunities for Iranian start-ups in a broad range of fields, such as tourism, architecture and urban life, nanopharmaceuticals, artificial intelligence, biotechnology, insurance, and financial innovations, content creation, and cybersecurity.
Increasing R&D in the field of nanopharmaceuticals is expected to boost growth of the EMEA nanopharmaceuticals market. For instance, in September 2019, researchers from the Institute for Chemistry and Bioanalytics, School of Life Sciences, University of Applied Sciences and Arts Northwestern Switzerland reported the use of ovarian cancer tissues to systematically identify concurrently overexpressed G-protein-coupled-receptors (GPCRs) and kinases. The study is expected to guide the future design of nanoparticles, which will dock to GPCRs on cancer cells via specific ligands and deliver anticancer compounds after receptor-mediated internalization. Moreover, in August 2018, researchers from the Hungarian Academy of Sciences and University of Pannonia reported the development of Doxorubicin and sorafenib co-loaded therapeutic nanocomposites using PLGA- and PEG-PLGA-encapsulating polymers, respectively. The nanoparticles offered potential physical and chemical properties with high yield, high drug encapsulation efficiency, and high drug loading.
Key Takeaways:
• Increasing adoption of targeted therapies for the treatment of chronic diseases is expected to propel growth of the EMEA nanopharmaceuticals market
• Increasing investment in R&D and government initiatives in the field of nanopharmaceuticals is also expected to boost growth of the market
• Major players operating in the EMEA nanopharmaceuticals market include Merck, Pfizer, Novartis, Abbott, GlaxoSmithKline, Roche, Sanofi, Eli Lilly and Company, Astrazeneca, Johnson & Johnson, Celgene, Novavax, and Stryker
Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Nanopharmaceuticals for these regions, from 2014 to 2025 (forecast)
Europe: Germany, France, UK, Russia, Italy and Benelux;
Middle East: Saudi Arabia, Israel, UAE and Iran;
Africa: South Africa, Nigeria, Egypt and Algeria.
EMEA Nanopharmaceuticals market competition by top manufacturers/players, with Nanopharmaceuticals sales volume (K Units), price (USD/Unit), Revenue (Million USD) and market share for each manufacturer/player; the top players including;
Merck
Pfizer
Novartis
Abbott
GlaxoSmithKline
Roche
Sanofi
Eli Lilly
Astrazeneca
Johnson & Johnson
Celgene
Novavax
Stryker
Gilead Sciences
OSI Pharmaceuticals
Kadmon Pharmaceuticals
Samyang Biopharm
Mitsubishi Pharma
Kaken Pharmaceutical
Selecta Biosciences
Par Pharmaceutical
Cerulean Pharma
Navidea Biopharmaceuticals
Lummy
On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into;
--Liposomes
--Polymeric Micelles
--Solid Lipid Nanoparticles
--Microemulsion And Nanoemulsion
--Nanosuspension
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Nanopharmaceuticals for each application, including;
--Cancer
--Tumor
--Autoimmune Disorders
If you have any special requirements, please let us know and we will offer you the report as you want.
Table of Contents
EMEA (Europe, Middle East and Africa) Nanopharmaceuticals Market Report 2019
1 Nanopharmaceuticals Overview
1.1 Product Overview and Scope of Nanopharmaceuticals
1.2 Classification of Nanopharmaceuticals
1.2.1 EMEA Nanopharmaceuticals Market Size (Sales) Comparison by Type (2014-2024)
1.2.2 EMEA Nanopharmaceuticals Market Size (Sales) Market Share by Type (Product Category) in 2018
1.2.3 Liposomes
1.2.4 Polymeric Micelles
1.2.5 Solid Lipid Nanoparticles
1.2.6 Microemulsion And Nanoemulsion
1.2.7 Nanosuspension
1.3 EMEA Nanopharmaceuticals Market by Application/End Users
1.3.1 EMEA Nanopharmaceuticals Sales (Volume) and Market Share Comparison by Application (2014-2024
1.3.2 Cancer
1.3.3 Tumor
1.3.4 Autoimmune Disorders
1.4 EMEA Nanopharmaceuticals Market by Region
1.4.1 EMEA Nanopharmaceuticals Market Size (Value) Comparison by Region (2014-2024)
1.4.2 Europe Status and Prospect (2014-2024)
1.4.3 Middle East Status and Prospect (2014-2024)
1.4.4 Africa Status and Prospect (2014-2024)
1.5 EMEA Market Size (Value and Volume) of Nanopharmaceuticals (2014-2024)
1.5.1 EMEA Nanopharmaceuticals Sales and Growth Rate (2014-2024)
1.5.2 EMEA Nanopharmaceuticals Revenue and Growth Rate (2014-2024)
2 EMEA Nanopharmaceuticals Competition by Manufacturers/Players/Suppliers, Region, Type and Application
2.1 EMEA Nanopharmaceuticals Market Competition by Players/Manufacturers
2.1.1 EMEA Nanopharmaceuticals Sales Volume and Market Share of Major Players (2014-2019)
2.1.2 EMEA Nanopharmaceuticals Revenue and Share by Players (2014-2019)
2.1.3 EMEA Nanopharmaceuticals Sale Price by Players (2014-2019)
2.2 EMEA Nanopharmaceuticals (Volume and Value) by Type/Product Category
2.2.1 EMEA Nanopharmaceuticals Sales and Market Share by Type (2014-2019)
2.2.2 EMEA Nanopharmaceuticals Revenue and Market Share by Type (2014-2019)
2.2.3 EMEA Nanopharmaceuticals Sale Price by Type (2014-2019)
2.3 EMEA Nanopharmaceuticals (Volume) by Application
2.4 EMEA Nanopharmaceuticals (Volume and Value) by Region
2.4.1 EMEA Nanopharmaceuticals Sales and Market Share by Region (2014-2019)
2.4.2 EMEA Nanopharmaceuticals Revenue and Market Share by Region (2014-2019)
2.4.3 EMEA Nanopharmaceuticals Sales Price by Region (2014-2019)
3 Europe Nanopharmaceuticals (Volume, Value and Sales Price), by Players, Countries, Type and Application
3.1 Europe Nanopharmaceuticals Sales and Value (2014-2019)
3.1.1 Europe Nanopharmaceuticals Sales Volume and Growth Rate (2014-2019)
3.1.2 Europe Nanopharmaceuticals Revenue and Growth Rate (2014-2019)
3.2 Europe Nanopharmaceuticals Sales and Market Share by Type
3.3 Europe Nanopharmaceuticals Sales and Market Share by Application
3.4 Europe Nanopharmaceuticals Sales Volume and Value (Revenue) by Countries
3.4.1 Europe Nanopharmaceuticals Sales Volume by Countries (2014-2019)
3.4.2 Europe Nanopharmaceuticals Revenue by Countries (2014-2019)
3.4.3 Germany Nanopharmaceuticals Sales and Growth Rate (2014-2019)
3.4.4 France Nanopharmaceuticals Sales and Growth Rate (2014-2019)
3.4.5 UK Nanopharmaceuticals Sales and Growth Rate (2014-2019)
3.4.6 Russia Nanopharmaceuticals Sales and Growth Rate (2014-2019)
3.4.7 Italy Nanopharmaceuticals Sales and Growth Rate (2014-2019)
3.4.8 Benelux Nanopharmaceuticals Sales and Growth Rate (2014-2019)
4 Middle East Nanopharmaceuticals (Volume, Value and Sales Price), by Region, Type and Application
4.1 Middle East Nanopharmaceuticals Sales and Value (2014-2019)
4.1.1 Middle East Nanopharmaceuticals Sales Volume and Growth Rate (2014-2019)
4.1.2 Middle East Nanopharmaceuticals Revenue and Growth Rate (2014-2019)
4.2 Middle East Nanopharmaceuticals Sales and Market Share by Type
4.3 Middle East Nanopharmaceuticals Sales and Market Share by Application
4.4 Middle East Nanopharmaceuticals Sales Volume and Value (Revenue) by Countries
4.4.1 Middle East Nanopharmaceuticals Sales Volume by Countries (2014-2019)
4.4.2 Middle East Nanopharmaceuticals Revenue by Countries (2014-2019)
4.4.3 Saudi Arabia Nanopharmaceuticals Sales and Growth Rate (2014-2019)
4.4.4 Israel Nanopharmaceuticals Sales and Growth Rate (2014-2019)
4.4.5 UAE Nanopharmaceuticals Sales and Growth Rate (2014-2019)
4.4.6 Iran Nanopharmaceuticals Sales and Growth Rate (2014-2019)
5 Africa Nanopharmaceuticals (Volume, Value and Sales Price) by Players, Countries, Type and Application
5.1 Africa Nanopharmaceuticals Sales and Value (2014-2019)
5.1.1 Africa Nanopharmaceuticals Sales Volume and Growth Rate (2014-2019)
5.1.2 Africa Nanopharmaceuticals Revenue and Growth Rate (2014-2019)
5.2 Africa Nanopharmaceuticals Sales and Market Share by Type
5.3 Africa Nanopharmaceuticals Sales and Market Share by Application
5.4 Africa Nanopharmaceuticals Sales Volume and Value (Revenue) by Countries
5.4.1 Africa Nanopharmaceuticals Sales Volume by Countries (2014-2019)
5.4.2 Africa Nanopharmaceuticals Revenue by Countries (2014-2019)
5.4.3 South Africa Nanopharmaceuticals Sales and Growth Rate (2014-2019)
5.4.4 Nigeria Nanopharmaceuticals Sales and Growth Rate (2014-2019)
5.4.5 Egypt Nanopharmaceuticals Sales and Growth Rate (2014-2019)
5.4.6 Algeria Nanopharmaceuticals Sales and Growth Rate (2014-2019)
6 EMEA Nanopharmaceuticals Manufacturers/Players Profiles and Sales Data
6.1 Merck
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Nanopharmaceuticals Product Type, Application and Specification
6.1.2.1 Product A
6.1.2.2 Product B
6.1.3 Merck Nanopharmaceuticals Sales, Revenue, Price and Gross Margin (2014-2019)
6.1.4 Main Business/Business Overview
6.2 Pfizer
6.2.1 Company Basic Information, Manufacturing Base and Competitors
6.2.2 Nanopharmaceuticals Product Type, Application and Specification
6.2.2.1 Product A
6.2.2.2 Product B
6.2.3 Pfizer Nanopharmaceuticals Sales, Revenue, Price and Gross Margin (2014-2019)
6.2.4 Main Business/Business Overview
6.3 Novartis
6.3.1 Company Basic Information, Manufacturing Base and Competitors
6.3.2 Nanopharmaceuticals Product Type, Application and Specification
6.3.2.1 Product A
6.3.2.2 Product B
6.3.3 Novartis Nanopharmaceuticals Sales, Revenue, Price and Gross Margin (2014-2019)
6.3.4 Main Business/Business Overview
6.4 Abbott
6.4.1 Company Basic Information, Manufacturing Base and Competitors
6.4.2 Nanopharmaceuticals Product Type, Application and Specification
6.4.2.1 Product A
6.4.2.2 Product B
6.4.3 Abbott Nanopharmaceuticals Sales, Revenue, Price and Gross Margin (2014-2019)
6.4.4 Main Business/Business Overview
6.5 GlaxoSmithKline
6.5.1 Company Basic Information, Manufacturing Base and Competitors
6.5.2 Nanopharmaceuticals Product Type, Application and Specification
6.5.2.1 Product A
6.5.2.2 Product B
6.5.3 GlaxoSmithKline Nanopharmaceuticals Sales, Revenue, Price and Gross Margin (2014-2019)
6.5.4 Main Business/Business Overview
6.6 Roche
6.6.1 Company Basic Information, Manufacturing Base and Competitors
6.6.2 Nanopharmaceuticals Product Type, Application and Specification
6.6.2.1 Product A
6.6.2.2 Product B
6.6.3 Roche Nanopharmaceuticals Sales, Revenue, Price and Gross Margin (2014-2019)
6.6.4 Main Business/Business Overview
6.7 Sanofi
6.7.1 Company Basic Information, Manufacturing Base and Competitors
6.7.2 Nanopharmaceuticals Product Type, Application and Specification
6.7.2.1 Product A
6.7.2.2 Product B
6.7.3 Sanofi Nanopharmaceuticals Sales, Revenue, Price and Gross Margin (2014-2019)
6.7.4 Main Business/Business Overview
6.8 Eli Lilly
6.8.1 Company Basic Information, Manufacturing Base and Competitors
6.8.2 Nanopharmaceuticals Product Type, Application and Specification
6.8.2.1 Product A
6.8.2.2 Product B
6.8.3 Eli Lilly Nanopharmaceuticals Sales, Revenue, Price and Gross Margin (2014-2019)
6.8.4 Main Business/Business Overview
6.9 Astrazeneca
6.9.1 Company Basic Information, Manufacturing Base and Competitors
6.9.2 Nanopharmaceuticals Product Type, Application and Specification
6.9.2.1 Product A
6.9.2.2 Product B
6.9.3 Astrazeneca Nanopharmaceuticals Sales, Revenue, Price and Gross Margin (2014-2019)
6.9.4 Main Business/Business Overview
6.10 Johnson & Johnson
6.10.1 Company Basic Information, Manufacturing Base and Competitors
6.10.2 Nanopharmaceuticals Product Type, Application and Specification
6.10.2.1 Product A
6.10.2.2 Product B
6.10.3 Johnson & Johnson Nanopharmaceuticals Sales, Revenue, Price and Gross Margin (2014-2019)
6.10.4 Main Business/Business Overview
6.11 Celgene
6.12 Novavax
6.13 Stryker
6.14 Gilead Sciences
6.15 OSI Pharmaceuticals
6.16 Kadmon Pharmaceuticals
6.17 Samyang Biopharm
6.18 Mitsubishi Pharma
6.19 Kaken Pharmaceutical
6.20 Selecta Biosciences
6.21 Par Pharmaceutical
6.22 Cerulean Pharma
6.23 Navidea Biopharmaceuticals
6.24 Lummy
7 Nanopharmaceuticals Manufacturing Cost Analysis
7.1 Nanopharmaceuticals Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Nanopharmaceuticals
8 Industrial Chain, Sourcing Strategy and Downstream Buyers
8.1 Nanopharmaceuticals Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Nanopharmaceuticals Major Manufacturers in 2018
8.4 Downstream Buyers
9 Marketing Strategy Analysis, Distributors/Traders
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List
10 Market Effect Factors Analysis
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change
11 EMEA Nanopharmaceuticals Market Forecast (2019-2024)
11.1 EMEA Nanopharmaceuticals Sales, Revenue and Price Forecast (2019-2024)
11.1.1 EMEA Nanopharmaceuticals Sales and Growth Rate Forecast (2019-2024)
11.1.2 EMEA Nanopharmaceuticals Revenue and Growth Rate Forecast (2019-2024)
11.1.3 EMEA Nanopharmaceuticals Price and Trend Forecast (2019-2024)
11.2 EMEA Nanopharmaceuticals Sales, Revenue and Growth Rate Forecast by Region (2019-2024)
11.3 Europe Nanopharmaceuticals Sales, Revenue and Growth Rate Forecast by Region (2019-2024)
11.4 Middle Eastt Nanopharmaceuticals Sales, Revenue and Growth Rate Forecast by Region (2019-2024)
11.5 Africa Nanopharmaceuticals Sales, Revenue and Growth Rate Forecast by Region (2019-2024)
11.6 EMEA Nanopharmaceuticals Sales Forecast by Type (2019-2024)
11.7 EMEA Nanopharmaceuticals Sales Forecast by Application (2019-2024)
12 Research Findings and Conclusion
13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
Request Discount 
Inquire Before Buy
